Cargando…

Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial

BACKGROUND/AIMS: Solifenacin, a muscarinic type 3 receptor antagonist, is used to treat overactive bladder in adults. The aim of this study is to examine the efficacy of solifenacin on the symptomatic relief of diarrhea predominant irritable bowel syndrome (IBS-D). METHODS: A total of 20 patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukushima, Yasushi, Suzuki, Hidekazu, Matsuzaki, Juntaro, Kiyosue, Arihiro, Hibi, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Neurogastroenterology and Motility 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400820/ https://www.ncbi.nlm.nih.gov/pubmed/22837880 http://dx.doi.org/10.5056/jnm.2012.18.3.317

Ejemplares similares

Are Solifenacin and Ramosetron Really Ideal to Treat Irritable Bowel Syndrome?: Author's Reply
por: Suzuki, Hidekazu, et al.
Publicado: (2012)

What Is the Difference Between Helicobacter pylori-Associated Dyspepsia and Functional Dyspepsia?
por: Suzuki, Hidekazu, et al.
Publicado: (2011)

Ghrelin and oxidative stress in gastrointestinal tract
por: Suzuki, Hidekazu, et al.
Publicado: (2011)

Overlap Syndrome of Functional Dyspepsia and Irritable Bowel Syndrome - Are Both Diseases Mutually Exclusive?
por: Suzuki, Hidekazu, et al.
Publicado: (2011)

Are Solifenacin and Ramosetron Really Ideal to Treat Irritable Bowel Syndrome?
por: Chang, Full-Young
Publicado: (2012)

Clinical Efficacy of Telemedicine Compared to Face-to-Face Clinic Visits for Smoking Cessation: Multicenter Open-Label Randomized Controlled Noninferiority Trial
por: Nomura, Akihiro, et al.
Publicado: (2019)

MicroRNAs in Barrett's esophagus: future prospects
por: Matsuzaki, Juntaro, et al.
Publicado: (2014)

Pharmacokinetics comparison of solifenacin tartrate and solifenacin succinate: a randomized, open-label, single-dose, 2-way crossover study in healthy male volunteers
por: Kim, Yu-mi, et al.
Publicado: (2018)

Targeted therapies for diarrhea-predominant irritable bowel syndrome
por: Olden, Kevin W
Publicado: (2012)

Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
por: Lacy, Brian E
Publicado: (2016)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Özdener, Ayşe Elif, et al.
Publicado: (2017)

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
por: Cash, Brooks D, et al.
Publicado: (2017)

Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea
por: Ida, Motoko, et al.
Publicado: (2017)

Role of MicroRNAs-221/222 in Digestive Systems
por: Matsuzaki, Juntaro, et al.
Publicado: (2015)

Circulating microRNAs as potential biomarkers to detect transformation of Barrett’s oesophagus to oesophageal adenocarcinoma
por: Matsuzaki, Juntaro, et al.
Publicado: (2017)

Misinterpreting Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea: Pathophysiological Highlights
por: Sciumè, Giusi Desirè, et al.
Publicado: (2023)

Acupuncture for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Randomized Clinical Trial
por: Qi, Ling-Yu, et al.
Publicado: (2022)

Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy
por: Hirata, Kenro, et al.
Publicado: (2013)

Influence of regular exercise on gastric emptying in healthy men: a pilot study
por: Matsuzaki, Juntaro, et al.
Publicado: (2016)

Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
por: Fragkos, Konstantinos C
Publicado: (2017)

Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update
por: Andrews, Christopher N, et al.
Publicado: (2019)

Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea
por: Colomier, Esther, et al.
Publicado: (2021)

Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome
por: Chiba, Toshimi, et al.
Publicado: (2013)

The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study
por: Lee, Seok-Hoon, et al.
Publicado: (2018)

Correction: Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication
por: Saito, Yoshimasa, et al.
Publicado: (2013)

Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication
por: Saito, Yoshimasa, et al.
Publicado: (2012)

Precision Medicine Approaches to Prevent Gastric Cancer
por: Matsuzaki, Juntaro, et al.
Publicado: (2021)

Response to letter regarding: development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication
por: Mori, Hideki, et al.
Publicado: (2022)

An Open-Label Trial Study of Quality-of-Life Assessment in Irritable Bowel Syndrome and Their Treatment
por: Alexandru, Bogdana Ariana, et al.
Publicado: (2022)

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016)

Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2018)

Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome
por: Li, Pingping, et al.
Publicado: (2020)

Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome
por: Zhan, Kai, et al.
Publicado: (2020)

Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Lembo, Anthony, et al.
Publicado: (2020)

Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: A randomized controlled trial
por: Zheng, Hui, et al.
Publicado: (2016)

Irritable bowel syndrome: Is it “irritable brain” or “irritable bowel”?
por: Padhy, Susanta Kumar, et al.
Publicado: (2015)

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
por: Kaku, Kohei, et al.
Publicado: (2014)

Dysregulation of GABAergic Signalling Contributes in the Pathogenesis of Diarrhea-predominant Irritable Bowel Syndrome
por: Aggarwal, Surbhi, et al.
Publicado: (2018)

Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome
por: Arrouk, Rami, et al.
Publicado: (2018)

Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome
por: Katsumata, Ryo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nbgojk4haabvg3fpdb4kradl0u